Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

AngioDynamics (NASDAQ:ANGO) is scheduled to report Q1 earnings on October 2, with analysts projecting a wider loss of 12 cents per share year-over-year, alongside an increase in revenue to $72.69 million. This follows the company's better-than-expected Q4 results and strong FY26 revenue guidance, which contributed to a 4% stock increase to $11.17. Major analysts, including HC Wainwright & Co. and Canaccord Genuity, maintain Buy ratings on ANGO, with price targets reaching up to $17, signaling continued positive sentiment ahead of the upcoming report.

Analysis

AngioDynamics (NASDAQ:ANGO) is set to report first-quarter earnings with a mixed set of analyst expectations. While quarterly revenue is projected to grow a solid 7.7% year-over-year to $72.69 million, this is coupled with an anticipated widening of the net loss to 12 cents per share from 11 cents in the prior-year period. This context is critical as it follows a strong fourth-quarter report on July 15, which featured better-than-expected results and an optimistic FY26 revenue guidance that surpassed estimates. The market and analyst community appear to be focused on this positive long-term outlook, evidenced by a recent 4% share price increase to $11.17 and bullish post-Q4 ratings from firms like Canaccord Genuity, which raised its price target to $17. The current investor sentiment seems to prioritize the company's growth trajectory over immediate profitability concerns, creating a key tension point heading into the earnings announcement.

Key Decisions for Investors

• Investors should weigh the company's projected 7.7% Q1 revenue growth and strong analyst price targets against the risk presented by a widening near-term loss per share.
• The upcoming earnings report is a key catalyst; focus should be on whether revenue meets the $72.69 million forecast and if management reaffirms the positive FY26 guidance, as these will likely be the primary drivers of the stock's direction.
• Considering the significant upside implied by analyst targets of $16-$17 versus the current $11.17 price, investors with a long-term growth focus may see an opportunity, but should be prepared for potential volatility if near-term losses are greater than expected.